INH14, a Small-Molecule Urea Derivative, Inhibits the IKKα/β-Dependent TLR Inflammatory Response.


Journal

Chembiochem : a European journal of chemical biology
ISSN: 1439-7633
Titre abrégé: Chembiochem
Pays: Germany
ID NLM: 100937360

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 22 10 2018
pubmed: 18 11 2018
medline: 31 12 2019
entrez: 18 11 2018
Statut: ppublish

Résumé

N-(4-Ethylphenyl)-N'-phenylurea (INH14) is a fragment-like compound that inhibits the toll-like receptor 2 (TLR2)-mediated inflammatory activity and other inflammatory pathways (i.e., TLR4, TNF-R and IL-1R). In this study, we determined the molecular target of INH14. Overexpression of proteins that are part of the TLR2 pathway in cells treated with INH14 indicated that the target lay downstream of the complex TAK1/TAB1. Immunoblot assays showed that INH14 decreased IkBα degradation in cells activated by lipopeptide (TLR2 ligand). These data indicated the kinases IKKα and/or IKKβ as the targets of INH14, which was confirmed with kinase assays (IC

Identifiants

pubmed: 30447158
doi: 10.1002/cbic.201800647
pmc: PMC6680106
doi:

Substances chimiques

NF-kappa B 0
Urea 8W8T17847W
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

710-717

Subventions

Organisme : Austrian Science Fund FWF
ID : P 30779
Pays : Austria

Informations de copyright

© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.

Références

Clin Cancer Res. 2009 Jan 15;15(2):425-30
pubmed: 19147746
J Recept Signal Transduct Res. 2015;35(4):307-18
pubmed: 25386663
Cytokine Growth Factor Rev. 2008 Apr;19(2):157-65
pubmed: 18308615
Eur J Med Chem. 2017 Aug 18;136:372-381
pubmed: 28525838
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2680-2689
pubmed: 28734965
Nat Immunol. 2004 Oct;5(10):975-9
pubmed: 15454920
Chembiochem. 2019 Mar 1;20(5):710-717
pubmed: 30447158
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Mol Cell Biol. 1994 Sep;14(9):5820-31
pubmed: 7520526
Biochem Pharmacol. 1994 Jan 13;47(1):145-9
pubmed: 8311838
Science. 1996 May 24;272(5265):1179-82
pubmed: 8638164
J Biol Chem. 2012 Jul 13;287(29):24641-8
pubmed: 22648407
Clin Microbiol Rev. 2008 Jan;21(1):13-25
pubmed: 18202435
ChemMedChem. 2014 Apr;9(4):813-22
pubmed: 24470159
Oncogene. 2006 Oct 30;25(51):6680-4
pubmed: 17072321
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5455-60
pubmed: 25870276
Bioorg Med Chem Lett. 2011 Apr 1;21(7):2106-12
pubmed: 21353546
J Med Chem. 2012 Feb 9;55(3):1189-204
pubmed: 22229669
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
pubmed: 20493977
Oncogene. 2006 Oct 30;25(51):6781-99
pubmed: 17072328
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Annu Rev Immunol. 2002;20:197-216
pubmed: 11861602
J Biol Chem. 2003 May 16;278(20):18485-90
pubmed: 12624112
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15058-63
pubmed: 18815378
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Semin Cancer Biol. 2019 Jun;56:12-24
pubmed: 29486318
Bioorg Med Chem. 2018 Sep 1;26(16):4615-4623
pubmed: 30093346
Oncogene. 2006 Oct 30;25(51):6685-705
pubmed: 17072322
FEBS J. 2018 Jun;285(12):2161-2181
pubmed: 29582565
Mediators Inflamm. 2010;2010:
pubmed: 20706656
EMBO Rep. 2014 Jan;15(1):46-61
pubmed: 24375677
Clin Diagn Lab Immunol. 2005 Jan;12(1):60-7
pubmed: 15642986
Eur J Med Chem. 2017 Jan 5;125:245-254
pubmed: 27688180
Oncotarget. 2014 Sep 15;5(17):7549-62
pubmed: 25277189
J Leukoc Biol. 2001 Jun;69(6):1036-44
pubmed: 11404392
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
Bioorg Med Chem. 2018 May 1;26(8):2041-2050
pubmed: 29534935
EMBO J. 2009 Jul 22;28(14):2018-27
pubmed: 19574958
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Cell. 2007 Sep 7;130(5):918-31
pubmed: 17803913
J Biol Chem. 2005 Nov 18;280(46):38133-45
pubmed: 16144834
J Immunol. 2011 Apr 15;186(8):4819-27
pubmed: 21402890
Nat Rev Drug Discov. 2010 Apr;9(4):293-307
pubmed: 20380038
J Biol Chem. 2001 Jul 20;276(29):27548-54
pubmed: 11335721
Sci STKE. 2006 Oct 17;2006(357):re13
pubmed: 17047224

Auteurs

Meinrad Drexel (M)

Department of Pharmacology, Medical University of Innsbruck, 6020, Innsbruck, Austria.

Johannes Kirchmair (J)

Department of Chemistry, University of Bergen, 5020, Bergen, Norway.
Computational Biology Unit (CBU), University of Bergen, 5020, Bergen, Norway.
Zentrum für Bioinformatik, Bundesstrasse 43, 20146, Hamburg, Germany.

Sandra Santos-Sierra (S)

Section of Biochemical Pharmacology, Medical University Innsbruck, Peter Mayr Strasse 1, 6020, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH